FDA Escalates Recall of Compounded GLP-1 Vials Amid Sterility Failures

Key points

• Apothecary Pharma is recalling 22 vials of compounded tirzepatide (18 mg/mL) due to lack of sterility assurance.
• The FDA upgraded the recall to Class II on October 10, 2026, following a December 2025 warning letter.
• Brand-name drugs like Mounjaro and Zepbound are not affected by this specific recall.
• Patients should check vial labels for lot numbers AP-202622 through AP-202644 and contact prescribers if affected.
• The FDA has received over 730 adverse event reports for compounded tirzepatide, though these are likely underreported.

Background

Compounded GLP-1 medications gained popularity during drug shortages in 2022, but production continued after shortages ended in 2024-2025. The FDA has since increased scrutiny on compounding pharmacies due to safety concerns. This recall follows a broader trend of FDA enforcement against compounding pharmacies for sterility and quality issues.

How outlets are covering it

The New York Post emphasizes the direct impact on patients using telehealth services, urging them to check labels. USA Today provides a broader context on the history of compounding pharmacy controversies, including the 2012 fungal meningitis outbreak. Medical Daily highlights a separate but related issue at Houston RX, where inspectors found 14 sterility violations, including exposed skin and research-grade ingredients, illustrating systemic issues in the compounding industry.

Why it matters

This recall underscores the risks associated with compounded medications, which are not FDA-approved for safety or efficacy. As millions of patients use compounded GLP-1s for weight loss, sterility failures pose significant health risks, including potential infections. The FDA's escalation signals a tightening of regulatory oversight on compounding pharmacies.

What to watch

Patients with affected lot numbers should stop using the medication and contact their prescribers for disposal instructions. The FDA may issue further warnings or legal actions against compounding pharmacies with repeated violations. Patients are advised to verify the legitimacy of their compounding pharmacy and consider FDA-approved alternatives.